🔴 UroGen Pharma is trading 5.6% down in pre-market as no clear cause is established

UroGen Pharma is trading 5.63% down at $32.00 in pre-market; no clear cause is established.

• Price context shows a pre-market decline from the October 27 close of $33.91.
• On October 28, the company announced positive five-year OLYMPUS follow-up results for JELMYTO, including durable responses and no observed progression to high-grade disease. Available coverage does not link the announcement to the decline.
• The broader indices provided are modestly higher and do not explain the move.